June 2014, Vol 4, No 4

Imbruvica (Ibrutinib) the First Bruton’s Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Relapsed Chronic Lymphocytic Leukemia

By Lisa A. Raedler, PhD, RPh

Imbruvica YOU&i Access Program and Support for Patients

Providing Social Support to Patients with Cancer

Practice Management

ICD-9 or ICD-10: What Is the Point?

By Karna W. Morrow, CPC, RCC, CCS-P, PCS

Coding and Billing, Reimbursement

Regardless of which version you are considering, the International Classification of Diseases, Clinical Modification (ICD-CM) is a morbidity classification published by the United States for classifying diagnoses and reasons for visits in all healthcare settings. Read More ›

Shopping for High-Quality, Affordable Oncology Care

By Carla Balch, CEO

Drug Compounding: New Rule a Game Changer for Oncology Practices

By Dawn Holcombe, MBA, FACMPE, ACHE

From the Editor

Fair Labor Standards Act: Exemptions Review

By Robert D. Orzechowski, MBA, SPHR, SHRM-SCP

Do’s and Don’ts in Physician-Hospital Alignment, Part 1

By Max Reiboldt, CPA

Practice Management

FDA-Approved Medications Used for the Treatment of Lung Cancer

New Clinical Trials Under Way

Clinical Trials Tracker